Introduction
The advent of the human genome project has created unique opportunities for the development and application of gene therapy to human diseases. The insertion of specific genes into target cells or organs holds the potential to revolutionise future medical treatment. A number of gene delivery systems are presently being developed for subsequent application in man. However elegant such vectors may be in a laboratory environment, in the clinical forum some of the most important aspects of gene therapy include the assessment of the efficacy of gene delivery, gene expression and the subsequent therapeutic benefit in vivo in man. In many instances, these vectors have been shown to be relatively effective within the confines of in vitro systems and even animal models, but they have proven to be less so when transferred to the clinical setting. This has partly arisen from the previous unavailability of suitable in vivo methods for the assessment of the expression of the delivered target gene. Moreover, in many instances there is a lack of monitoring modalities that can assess the efficacy of these emerging therapies. There is therefore an urgent need for in vivo clinical methodologies that allow gene delivery, uptake, patient with noninvasive detection of transgene expression in vivo in man. Similarly, magnetic resonance spectroscopy is being developed as a noninvasive method to assess transgene expression indirectly by means of MR visible intracellular markers. These markers take the form of intracellular endo/exogenous metabolites associated with exogenous enzyme expression and function. Again, this technique will be applicable to a variety of different situations, from cell suspensions through to clinical imaging of the whole body. In this article the unique opportunities for laboratory-based and clinical studies afforded by MR techniques are discussed. Gene Therapy (2000) 7, 1259-1264.
expression and subsequent therapeutic changes to be mapped out in the body with a view to tailoring gene therapies to individual patient requirements.
In this context, there are a number of noninvasive imaging methods that are currently under development for in vivo monitoring purposes in man. These include standard clinical imaging techniques such as ultrasound and computerised tomography (CT) and other existing modalities which have until now largely remained a preserve of the research environment such as positron emission tomography (PET) and single photon emission tomography (SPECT).
1 New technologies such as electric source imaging (using electroencephalographic or electrocardigraphic techniques), 2, 3 electrical impedance mapping, 4 magnetic field gradient measurements (magnetoencephalography or magnetocardiography), 5, 6 microwave scattering tomography 7 and bioluminescence techniques 8 are also under assessment for use in man. However, uniquely, magnetic resonance (MR) techniques bridge the gap between technologies that have gained everyday acceptance in the clinical arena (magnetic resonance imaging, MRI) and those that still are research tools (magnetic resonance spectroscopy, MRS). The aim of the present article is to review the potential of MR techniques in the study of gene expression and gene therapy.
Magnetic resonance techniques
The nuclear magnetic resonance (NMR) phenomenon was first demonstrated experimentally in 1946, 9,10 but it was not until the early 1980s that it began to have its impact in clinical diagnosis and research. The last decade has seen a great deal of interest in the utilisation of NMR techniques to resolve clinical problems; the biomedical application being two-fold: MRI and MRS. MRI has become an increasingly available and accepted clinical imaging method, since its first human applications in the early 1980s. MRS provides direct biochemical information on the function of animal and human organs in vivo, on the integrity of isolated organs ex vivo, the composition of body fluids, tissue biopsies and intact cell suspensions in vitro.
A great advantage of both MRI and MRS is that they are noninvasive, safe and reproducible, and can be repeated to allow serial information to be collected or in the case of MRS, dynamic biochemical changes to be observed. Furthermore, MR techniques can encompass both the laboratory (high resolution MRS in animal studies or in vitro) and clinical needs (whole body MR scanning).
In vivo MR studies are normally carried out using large, whole body superconducting magnets. The strength of magnetic fields is usually measured in Tesla (T) with most clinical MRI systems operating between 0.5 and 1.5 T. The usual field strength of magnets employed for whole body (in vivo) MRS is 1.5 T, although there are clinical research systems which operate at 4.7 T and some at 8 T. With increasing magnetic field strengths, improved sensitivity and resolution is achieved, but the cost of high field whole body systems (Ͼ2 T) is at the moment rather prohibitive. In vitro MRS of body fluids, cell suspensions and tissue samples, and/or detailed MR imaging at the cellular level ('MRI microscopy') are often performed at up to 11.7 T, far beyond the range of the wide bore clinical systems used for human or even animal studies.
MR overview
MR sensitive nuclei such as hydrogen-1 ( . 11 The resulting signal, known as the free induction decay (FID), can be resolved by a mathematical process known as Fourier transformation into either an image, providing anatomical information for MRI ( Figure 1A ) or a frequency spectrum, providing biochemical information, the basis of MRS ( Figure 1B ).
MR Imaging (MRI)
The ability to generate images of intact living objects noninvasively and nondestructively has made MRI one of the leading imaging modalities. In general, MR images consist of high resolution maps of the intracellular tissue water ( Figure 1A ). The contrast normally observed in an MR image therefore corresponds to differences in content and/or MR properties of water within different regions of a given organ or tissue. The clinical information, anatomical and/or dynamic, obtained in MRI examinations can be modified either by tailoring the MR pulse sequences to highlight or nullify signal from different water-containing (or fat) compartments in the body or by the use of MR contrast agents. Thus, excellent soft tissue contrast, and therefore discrimination of areas of interest, can be obtained by proper choice of experimental parameters. Amongst many applications, MRI techniques are being used to determine organ development or atrophy, angiography, functional imaging, dynamic changes in arterial blood flow or biliary drainage, for example.
Recent advances in high field magnets have permitted an expansion of the MRI modality into previously unforeseen areas of research. 12 This area of application, which has led to the imaging of isolates within cells, is termed 'MRI microscopy'. The resolution is about 1 m and in combination with contrast agents, which highlight physiological changes in the cell, opens up exciting possibilities.
MR contrast agents
The use of intravenously injected contrast agents is a well-established method for improving the conspicuity of certain body tissues and therefore for improving diagnostic yield in the clinical and research arenas. 13 MR contrast agents are usually biologically inert chelates of gadolinium or other paramagnetic elements such as iron and exert their action by altering MR relaxation times. 14, 15 Thus, the presence of gadolinium-based contrast agent, such as Gd-DTPA, results in areas of hyperintensity on MRI, while agents such as superparamagnetic iron oxides (SPIOs) cause hypointense areas on MRI. 16 However, the ability of a particular contrast agent to highlight a tissue depends on its specificity and molecular weight, if it is not freely diffusible. 17 Newer contrast agents have been developed which have particular affinity for particular body compartments such as the blood, bile, the hepatic parenchyma or the reticuloendothelial system. 18 For example in the liver, Gd-DTPA and manganese dipyridoxyl diphosphate concentrate in the parenchymal tissue and subsequently in the bile, producing a brightening of the liver, whereas SPIOs are taken up by Kupffer cells and other reticuloendothelial cells and produce hepatic darkening. 19 This is important in improving the conspicuity of focal lesions, especially in the context of a cirrhotic liver where tumours develop on the background of nodular regeneration. 20 
MR spectroscopy (MRS)
Information from MRS is normally presented in the form of a spectrum ( Figure 1B ). Whatever the chosen nucleus under MRS examination, the nuclei from individual metabolites resonate at a given frequency, depending on the chemical environment of each nucleus. This phenomenon is known as chemical shift. The intensity of each metabolite signal is related to the concentration of the metabolite. Analysis of the MR spectrum allows noninvasive insight into metabolite concentrations, intracellular pH and the metabolic state of pathological tissue, as well as dynamic changes in the metabolism of living tissue in both health and disease. 21 However, only compounds present at millimolar concentrations are normally detectable utilising the clinical MR systems currently available. 21 In vivo MRS Both 1 H and 31 P have a high natural abundance and therefore in vivo MRS studies using these nuclei do not require isotopic enrichment. These techniques have become an essential tool in biological and clinical research in areas as varied as brain, liver, heart, kidney and skeletal muscle function and metabolism. Data from 13 C is often more difficult to obtain, mainly because this nucleus has a natural abundance of 1.1%, whereas the most abundant carbon isotope, 12 C, is MR insensitive. Most in vivo 13 C MRS studies augment the MR signal by using 13 C labelled tracers to follow metabolic pathways in the body, 22 but good quality signals may be obtained from glycogen and adipose tissue without enrichment. 23, 24 In vitro MRS Intact tissue biopsies, cell suspensions, body fluids and tissue extracts can be examined by using in vitro MR spectroscopic techniques at much higher magnetic field strengths than the clinical systems. In vitro spectra are better resolved than those obtained from whole body tissue at 1.5 T, not only because of the higher magnetic field strengths used (11.7 T), but also because metabolites are uniformly distributed in solution. Solid state, as in an intact tissue biopsy, can be physically spun to remove residual imperfections in the homogeneity of the B 0 field. This latter technique is known as magic angle spinning. 25, 26 Quantitative information on multiple metabolites can be obtained from a single examination. This may allow more detailed characterisation of the biochemical changes observed in vivo in man. In vitro MRS and MR microscopy afford the possibility of assessing gene transfer and gene therapy at a cellular and isolated organ level before transferring such treatments to a clinical setting.
Detection of gene expression by MR
Analysis of gene delivery and expression in the clinical setting currently involves molecular assays of histological biopsy material. This greatly limits the applicability of this technique, since repeat biopsy, which would be necessary for longitudinal assessment of gene expression would be unethical and impractical. Therefore, the development and implementation of techniques that allow the detection, noninvasively and nondestructively, of gene expression is not only highly desirable, but appears to be essential for future implementation of gene therapy. This technique(s) should permit the definition not only of the location and magnitude, but also allow longitudinal determinations of gene expression.
There is no doubt that the most desirable technique to achieve this end, would be a method that allows the detection of gene expression both at transcriptional and translational level. This challenge has not as yet been met and to date there appears to be no generic MR marker for endogenous gene expression, since transcription products cannot be directly detected by existing MR modalities. Therefore, given the present technical constraints, researchers have opted for assessing gene expression indirectly. Thus, rather than detecting transcription products and/or protein accumulation directly, gene expression is being determined by looking at the biological action(s) of gene products. This approach hinges on the detection of enzymatic action at a cellular level and in MR terms can be broadly separated into two relatively distinct areas: (1) MRI detectable changes associated with metabolism of 'smart' contrast agents; and (2) MRS detection of cellular accumulation of 'marker metabolites'. In the first instance, gene expression is determined by assessing MRI-detectable changes in tissue water MR characteristics, following the 'metabolism' of a contrast agent by a marker enzyme. This has been possible by the development of a new generation of MRI contrast agents (so called 'smart contrast agents') that only provide tissue contrast in the presence of a preselected gene product. These agents have the potential to be 'switched on' and their signal observed both in high resolution cellular MRI (MRI microscopy) and in wholebody MR imaging. The second method for detecting gene expression in vivo hinges on the incorporation into gene delivery systems of genes that lead to cellular accumulation endogenous MRS-visible products or enzymes that metabolise preselected pharmacological compounds. Both of these MR-based approaches are being developed to monitor gene expression in vivo. Current and potential applications of these techniques are discussed below.
MR imaging and gene expression
A new emerging generation of contrast agents, so-called 'smart' contrasts agents, hold great promise in the gene therapy arena. These contrast agents have the potential to be 'switched on' in response to physiological changes within a cell, which in this context may be induced by the delivery of a preselected marker gene. Smart contrast agents were initially developed in the field of standard optical microscopy, and allowed changes in the physiology of intact cells to be mapped out. 27 This and similar techniques have not been readily transposable to whole functioning biological systems. However, this problem has been overcome by the development of such agents in the context of MRI, where their use would not only be applicable in the laboratory, but also in vivo in animal models and in man.
A new family of gadolinium chelates has been developed that can be cleaved by enzymatic action, changing their MR relaxation properties. In so doing they become activated, leading to significant changes in MR signal intensity, where previously there was none or relatively little. 28 This group of 'smart contrast agents'
includes EGad or [4,7,10-tri(acetic acid)-1-(2-␤-galactopyranosylethoxy)-1,4,7,10-tetraazacyclododecane] gadolinium. Exposure of EGad to the marker enzyme ␤-galactosidase (␤-gal) removes the galactopyranose from the cage of chelators surrounding the gadolinium ion and transforms the agent from a weak to a strong relaxivity state ( Figure 2) . 29 Given that ␤-gal is a widely used marker enzyme, EGad may allow the possibility of following gene expression patterns both in the laboratory (in cell culture and isolated organs and in animal models) and ultimately in man in vivo. 30 Currently methods of delivery of these agents are being worked upon. 29 Other 'smart' contrast agents have been developed, including compounds that are detectable by both fluorescent light microscopy and by MRI microscopy. These complexes possess a covalently attached fluorescent dye attached to a caged gadolinium chelate. An example is 1,4,7,10-tetraazacyclododecane-N,NЈ,NЉ,NЈЉ-tetraacetic acid (DOTA) which is bonded to tetramethylrhodamine. Again, the use of the ␤-gal gene as a marker, allows gene delivery and expression to be followed, since DOTA also changes its conformation in the presence of this enzyme and is thus activated to a stronger MR signal. At present these compounds have been used in the context of embryological development studies in MRI microscopy ( Figure 3 ), but could potentially be developed for use in man. 31 Further recent developments in 'smart' contrast agents include a caged gadolinium chelate, DOPTA-GD, which is sensitive to intracellular calcium concentrations. 32, 33 The compound changes its MR relaxivity as calcium concentrations increase within the cytoplasm and thus the MR detectable signal becomes more intense. Since Ca
2+
is an important intracellular messenger of signal transduction and is critical to the regulation of homeostasis, these compounds may provide a noninvasive way of measuring calcium fluxes after therapeutic intervention including gene delivery through viral or nonviral mechanisms.
A potential limitation of the use of these contrast agents, as with most exogenous compounds, has been their delivery to intact cells or tissues. However, the development of contrast agents that are covalently attached to biological macromolecules may overcome 
the embryo in (A) fluorescent and (B) MRI views. The eye is brightly fluorescent in panel A and displays a correspondingly strong signal in panel B (e, eye; np, nasal pit). In the top view (C), the difference in signal intensity within the neuraxis is striking. cg, cement gland which displays intense inherent signal unrelated to the injected contrast agent; s, somite; sc, skin cell. (Modified from Huber et al. Bioconjug Chem 1998; 9: 242-249 by permission of the American Chemical Society)
. 31 these problems of uptake into the cell. Gadolinium compounds conjugated to polylysine have been developed which bind to DNA electrostatically. 34 Binding of such a molecule to receptors on the cell surface delivers such DNA-ligand complexes into targeted cells or tissues. Kayyem and colleagues reported on the delivery of gadolinium chelates (Gd-DTPA) bound to poly-d-lysine in a DNA-ligand complex that included the following components: DNA encoding the firefly luciferase reporter gene and poly-l-lysine attached to human transferrin. Human T cell leukaemia-derived K562 cells were incubated with these DNA/polylysine/gadolinium complexes and MRI-detectable contrast enhancement was observed using MR microscopy at near single cell resolution. This methodology therefore combines MR detectable signals with a receptor-targeted gene delivery vehicle and provides a medium for tracking gene transfection and monitoring gene therapy. However, the efficacy of these agents in vivo is still to be established.
MR spectroscopy and gene expression
Magnetic resonance spectroscopy could play an important role in gene therapy, both as a tool to assess gene expression and as a noninvasive method to determine the efficacy of gene therapies. As outlined earlier, MRS can provide biochemical and metabolic information on intact cells, isolated organs or different areas of the body in vivo. [35] [36] [37] Moreover, its ability to detect signal noninvasively has been exploited to assess drug metabolism in vivo and in vitro. Changes in a MR spectrum brought about by delivery of exogenous (fluorinated, phosphorylated or 13 C enriched) or naturally occurring compounds may be detected using this technique. This ability is today being harnessed to development MRS as a noninvasive tool to detect gene expression, albeit indirectly.
MRS can be used to detect gene expression by assessing changes in metabolite levels of specific 'marker substrates'. These can take the form of prodrugs or specifically designed compounds that will be metabolised or synthesised by the marker enzyme. However, regardless of the approach it is important that the accumulation of the 'marker' substrate reflects gene expression and be proportional to the marker gene and the therapeutic gene. Thus, the marker metabolite needs to be nontoxic, not be metabolised by the host tissue (unless expressing the marker gene) and must accumulate within the transduced cells.
The approach of 'marker prodrug' has been utilised to detect cytosine deaminase (CD) transgene expression. 38 At present 19 F MRS is utilised to detect the effects of fluorinated drugs. For example, the chemotherapeutic agent, 5-fluorouracil (5FU) produces a strong signal when this MRS modality is used. 39 Cytosine deaminase catalyses the conversion of the prodrug, 5-fluorocytosine, to the active agent, 5FU. 40 Stegman et al 38 used the noninvasive quantification by 19 F MRS of 5FU to determine cytosine deaminase transgene expression (of microbial origin) in subcutaneous human colorectal carcinoma xenografts in nude mice. The technique demonstrates the feasibility of detecting the 5FU signal by MRS when the prodrug has been activated by exogenous delivery of the appropriate effector transgene. It serves as a suitable model for measuring effector gene expression and affords the possibility that the technique may find utility in subsequent clinical trials in man. Similar approaches can be developed, both at cellular and clinical level, with other clinically useful prodrugs, by means of The use of endogenous 'marker metabolites' has been illustrated by the use a nonmammalian marker gene. 31 P MRS was used in combination with an adenovirus vector to deliver a marker gene encoding the enzyme arginine kinase, from the Drosophila, to the muscle of adult mice. 41 The product of this enzyme is phosphoarginine, which is visible in the MR spectrum, but is not normally present in mammalian cells (Figure 4) . Experiments on neonatal mice have shown that this foreign genetic material is expressed for up to 8 months and thus this system offers a noninvasive means of monitoring transgene products and enzyme activity in vivo.
However, in man there may be ethical problems with delivering genetic material from other species for gene therapy purposes. Nevertheless, there are useful characteristics of innate human 31 P MR spectra that can be utilised for purposes of gene therapy without having to invoke xenogenetic material. Unlike spectra from other areas of the body such as muscle and brain, spectra acquired from the liver do not contain signal from phosphocreatine, since hepatocytes have a dual blood supply from the systemic and portal systems and do not express cytoplasmic creatine kinase, the enzyme responsible for the production of phosphocreatine. 42 This opens up the possibility of using the gene for cytoplasmic creatine kinase as an MR visible marker of gene transfection in gene therapy of the liver. Successful delivery of this marker Gene Therapy gene would allow detection of a phosphocreatine signal that was not previously evident. This technology if it were combined with a suitable hepatotropic gene delivery system such as the adenovirus or the baculovirus 43 may allow transfection experiments to be tracked through an MR-visible marker, not only in isolated cell culture, but potentially in vivo in man.
Finally, a fast although less specific method to detect transgene expression could be achieved by the use of in vitro MRS. 44, 45 This would be accomplished by measuring the level of 'marker metabolites' in body fluids such as urine, blood, CSF and bile, instead of transfected cells. This method would be limited to a binomial form of detecting gene expression, on/off, and would depend on the ability of the 'marker metabolites' to cross the cell membrane and accumulate in the body fluids. Nevertheless, this method could be relatively effective as a broad way of detecting transgene expression. One could envisage it as a fast and inexpensive first-pass approach to detect gene expression in human subjects, before more sophisticated in vivo methods are applied.
Conclusions
Analysis of gene delivery and expression in the clinical setting currently involves molecular assays of histological biopsy material, but MR techniques hold the promise of noninvasive and dynamic assessment of the location, magnitude and duration of transgene expression. The development of 'smart' contrast agents may allow the visualisation of the effects of gene expression through physiological changes within the cell that cause an increase in MRI-detectable signal, whereas the delivery of marker genes that encode for MR visible metabolites means that MR spectroscopy has exciting prospects in monitoring the effects of therapeutic intervention. Furthermore, both MR modalities are uniquely equipped to extend the monitoring role from the laboratory bench into the patient.
